SCHEMBL20244282

SCHEMBL20244282

COc1ccc(C(=O)/C=C/c2ccc([N+](=O)[O-])cc2O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.67
▸ MAOA P21397 1/20 0.67
▸ GABRA3 P34903 1/20 0.61
▸ GABRA2 P47869 1/20 0.61
▸ GABRB2 P47870 1/20 0.61
▸ ALDH1A1 P00352 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ TNFRSF1A P19438 1/20 0.57
▸ DPP4 P27487 2/20 0.54
▸ KRAS P01116 1/20 0.54
▸ PTPN1 P18031 1/20 0.54
▸ ABCG2 Q9UNQ0 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14305992 0.88 MAOB (0.67) MAOBMAOAGABRA3GABRA2GABRB2
SCHEMBL20244436 0.86 MAOA (0.50) MAOBMAOAGABRA3GABRA2GABRB2
SCHEMBL4139154 0.84 GABRA3 (0.78) MAOBGABRA3GABRA2GABRB2ALDH1A1
SCHEMBL28339980 0.84 GABRA3 (0.78) MAOBGABRA3GABRA2GABRB2ALDH1A1
SCHEMBL29083859 0.83 TYR (0.65) MAOBMAOAALDH1A1MAPTNPC1
SCHEMBL27631290 0.83 TYR (0.65) MAOBMAOAALDH1A1MAPTNPC1
SCHEMBL1603828 0.82 CHRNA7 (0.75) GABRA3GABRA2GABRB2ALDH1A1MAPT
SCHEMBL1603827 0.82 CHRNA7 (0.75) GABRA3GABRA2GABRB2ALDH1A1MAPT
SCHEMBL31326032 0.81 MAOB (1.00) MAOBMAOAALDH1A1MAPTSMN1; SMN2
SCHEMBL10658782 0.81 MAOB (1.00) MAOBMAOAALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3333153-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) 2018-06-13 — — EP disclosed
Send feedback